Arjun Ishwar is joining Miach Orthopaedics, Inc. as vice president of sales and marketing.
Miach, a privately held company based in Westborough, Massachusetts, develops bio-engineered surgical implants for connective tissue restoration. The company is currently focused on its Bridge-Enhanced® ACL Restoration (BEAR®) Implant, which helps the body heal its torn ACL. At Miach, Ishwar will lead the BEAR Implant commercialization efforts.
OTW spoke with Ishwar about joining the Miach team. Ishwar told OTW, “The BEAR Implant represents revolutionary change in medicine. While I have had the privilege of bringing multiple outstanding technologies to market, none have been more significant and clinically proven to impact patient care as the BEAR Implant.”
Ishwar continued, “Miach has displayed a unified passion for advancing the treatment of ACL tears. But more impressive has been the magnitude of surgeon and patient advocacy for this product. I could not be more proud to join this team to drive awareness and adoption of the BEAR Implant.”
This is not the first time that Ishwar has led commercial teams focused on bringing medical technologies to market. Most recently, he served as chief commercial officer of MY01, a medical device company focused on the detection of compartment syndrome.
Ishwar also spent almost 10 years at ACell, Inc., a developer of regenerative medicine products. At ACell, he served in roles of increasing responsibility. In his last position with the company, he was senior director and general manager, global acute wound reconstruction.
In addition to his marketing, product management, and medical device experience, Ishwar also has an engineering background. His Bachelor of Science and Master of Science degrees from Purdue University are in biomedical engineering.
Miach President and CEO Patrick McBrayer and Ishwar previously worked together at ACell. In the press release, McBrayer commented, “Arjun is a proven leader in the medical device field and has a strong track record of developing and implementing business strategies for medical technologies that improve patients’ lives. Lending his expertise to the BEAR Implant is a natural fit.”
McBrayer continued, “Our experience working together to drive adoption of tissue regeneration products will be invaluable as we continue the commercial rollout of the BEAR Implant in the U.S.”
